sandalwood

Key Takeaways:

1. Overall Market: Grew 9% YoY in Q1 with a V-shaped recovery; March surged to ¥740M, indicating a healthy seasonal structure.
2. Vitiligo Segment: Experienced explosive growth of 643% due to new targeted drugs, becoming the biggest structural driver of the quarter.
3. Traditional Antifungals: Saw internal market share shifts as legacy products face pressure and TCM (Traditional Chinese Medicine) alternatives emerge.
4. Pharma-Cosmetics Convergence: Accelerated by antibacterial acne treatments and functional skincare.

Market Overview: V-Shaped Recovery & Healthy Quarterly Performance

In Q1 2026, the dermatology e-commerce market grew 9% YoY. However, the underlying growth drivers have shifted. The divergence between sub-sectors is now more pronounced than in previous years; upcoming efficacy and product data will reveal exactly who is driving growth and who is facing pressure.

• January: Opened strong at ¥595M (+16% YoY). Driven by Chinese New Year promotions and winter medication stockpiling, this marked a rare high start for online dermatology sales.
• February: Dipped to ¥489M (-4% YoY) due to typical seasonal factors like holiday logistics constraints and diverted consumer attention, representing a normal cyclical trough.
• March: Surged back to ¥740M (+14% YoY) as spring allergies spiked. This rebound pushed the quarterly growth back into double digits, serving as the true stabilizer for Q1.

Structurally, growth was primarily fueled by the activation of new categories rather than broad acceleration across existing tracks—a trend that will be further validated at the efficacy level.

 Efficacy Landscape: Three Pillars Steady, Vitiligo Emerges as Disruptor

At the secondary efficacy level, the core market framework remains solid, but incremental growth is increasingly concentrating in niche segments.

The traditional three pillars continue to perform steadily:

• Tinea (Fungal Infections): Remains the top category at ¥644M (+6% YoY).
• Acne: Reached ¥309M (+9% YoY), maintaining healthy growth driven by consumer adoption of scientific skincare.
• Dermatitis & Eczema: Surpassed ¥300M (+4% YoY), supported by stable seasonal demand.

These three pillars account for over 60% of Q1 volume, serving as the foundation for market stability. Notably, structural divergence is emerging within tinea treatments: TCM options like Zuguang San are growing against the trend, signaling rising consumer acceptance of Chinese medicine for fungal infections.

The biggest structural variable in Q1 was the vitiligo segment.

It generated ¥87M in sales with a staggering +643% YoY surge. This was not organic growth, but rather a category activation triggered by the launch and rapid e-commerce penetration of China's first targeted vitiligo drug (ruxolitinib cream) earlier this year.

Historically, vitiligo had strong clinical demand but limited treatment options. The approval of this single drug unlocked pent-up purchasing intent among existing patients, causing a concentrated release of demand. This mirrors the early explosive logic of the GLP-1 weight-loss segment: breakthrough drugs fill genuine clinical gaps, while e-commerce provides a fast channel for penetration, leading to phenomenal short-term growth.

Meanwhile, the psoriasis segment showed promising growth signals. As biologics and topical targeted drugs become more accessible online, prescription-consumer products like calcipotriol and tacalcitol are building a stable base of repeat buyers, representing significant mid-term potential.

Conversely, some categories face short-term pressure: Scars (-17%), Antibacterial/Anti-inflammatory (-12%), and Warts/Herpes (-6%). These segments are experiencing structural headwinds from competitive substitution or fragmented demand, with no immediate catalysts for self-driven recovery.

Product Trends: Innovation and Classics Coexist

In Q1's high-growth product rankings, innovative drugs and established generics exhibited a distinct dual-track pattern.

• Innovative Drugs: Ruxolitinib cream, a targeted drug approved in early 2026, surged to the #2 spot across all categories with over ¥80M in sales. Driven by high clinical attention and unmet patient needs, its average order value (AOV) reached ¥5,805. This confirms that when clinical efficacy is highly certain, patients' willingness to pay easily overrides price constraints—a logic identical to the GLP-1 weight-loss market.
• Established Generics: Mupirocin ointment (+36%) and Adapalene gel (+33%) continued to lead in antibacterial and acne segments, proving that consumer trust in medical-grade acne treatments is now mature and stable.
• TCM & Functional Skincare: Zuguang San represents a TCM revival. Meanwhile, Tretinoin and Urea-Vitamin E creams rode the "skin barrier repair" trend to achieve double-digit growth during spring dryness, showing how classic ingredients can experience a second boom under new consumer narratives.

Key Takeaway: Products backed by clear clinical evidence or upgraded efficacy narratives—whether old or new—consistently outperform the broader market on e-commerce. Conversely, legacy products relying solely on historical fame without fresh storytelling are facing structural pressure from depleting existing demand.

Pharma-Cosmetics Convergence: Capital Validates Trend, Data Confirms Growth

The boundary between pharma and cosmetics blurred significantly over the past year, with capital interactions hitting a multi-year high. From L'Oréal-backed funds investing in local dermatology firms to top beauty brands backing healthcare funds, capital flows clearly show that the beauty industry is using investments to secure scientific endorsements for medical ingredients, aiming to overcome growth stagnation as mass-market beauty dividends peak.

This trend is directly validated by e-commerce sales data. In Jan–Apr 2026, non-retinoid drugs grew 40% YoY, while retinoid drugs grew 19% YoY—both significantly outpacing the broader dermatology market.

These categories share a common trait: their efficacy narrative has successfully crossed over from "treatment" to "skin improvement," making them the top choice for ingredient-savvy consumers across both pharma and beauty scenarios. The core mechanism behind this shift is superior cost-performance; pharmaceuticals offer equal or stronger active ingredients at drug-tier pricing, creating a natural price advantage over comparable beauty products.

Conclusion:

Looking back at Q1 2026, the dermatology e-commerce market sent clear structural signals: once innovative targeted drugs fill genuine clinical gaps, their explosive growth on e-commerce far exceeds expectations. Meanwhile, mature tracks like tinea are experiencing internal structural divergence, with TCM pathways offering sustained growth opportunities.

Heading into Q2, as seasonal allergy demand recedes, competition will intensify in stable segments like acne and psoriasis. As traffic costs continue to rise, identifying which brands can defend their market share and which categories still possess structural growth potential will be the most critical topics to track in the second half of the year.